bpc-157 safety human trials adverse effects BPC-157 and the Difference Between an Evidence Gap The Peptide Gold Rush -

For those considering peptide therapy, this uncertainty itself is a safety risk: an impure or mislabeled product can cause unexpected reactions that confound reproductive plans

not for human or veterinary applications

But BPC 157 seems really safe

Therefore, we defend stable gastric pentadecapeptide BPC 157 therapys efficacy and pleiotropic beneficial effects, along with its high safety (LD1 not achieved), against speculation of its negative impact, speculation of angiogenesis toward tumorigenesis, increased NO and eNOS, damaging free radical formation, and neurodegenerative diseases (Parkinsons disease and Alzheimers disease)

Thymosin alpha-1 immune rebalancing effects may take 4 to 8 weeks to manifest clinically

During rest, when tissue restoration takes place naturally, this peptide can operate effectively